Dalbavancin side effects: what 976 FDA adverse event reports show

Dalbavancin · 14 reaction terms · 162 drug–reaction co-reports · data 2026-09-14

Drug class

Lipoglycopeptide antibacterial

FDA label, Indications wording

Who reports

976 reports · 44% serious · 21 with death outcome · 48% female

openFDA FAERS counts, all years, deduplication not applied

Used for

Dalbavancin for Injection is a lipoglycopeptide antibacterial indicated for the treatment of adult and pediatric patients with acute bacterial skin and skin structure infections (ABSSSI) caused by designated susceptible strains of Gram-positive microorganisms.

FDA label, Indications and Usage

What it is

Dalbavancin for Injection is a lipoglycopeptide antibacterial synthesized from a fermentation product of Nonomuraea species. Dalbavancin is a mixture of five closely related active homologs (A 0 , A 1 , B 0 , B 1 , and B 2 ); the component B 0 is the major component of dalbavancin.

FDA label, Description section

Boxed warning

None in the current label

How to read this page. FAERS is a spontaneous-reporting system: counts are not incidence rates and a signal is not proof of causation. Each reaction below is run through an automated screen — is the term in the FDA label (known), in the indications (the disease being treated), an administrative/coding term, or none of these (unlabeled)? That screen is mechanical text matching, not a causality assessment. The 30 hand-written Bradford Hill assessments are on the causality assessment page. Not medical advice.

Causality screen of the 11 strongest signals

Labeled adverse reaction 2Labeled (related wording) 2Reporting / coding artifact 3Not in label — unassessed 4

What the badges mean

Labeled adverse reaction The exact term appears in the label's warnings or adverse-reactions sections: a known, expected effect. The FAERS signal confirms the label rather than discovering anything.
Labeled (related wording) The label describes this effect under different wording (e.g. 'neutropenia' for 'neutrophil count decreased'). Treated as known.
Reporting / coding artifact An administrative, monitoring or exposure term (product issue, off-label use, 'test normal', overdose...). Not a biological reaction; a high PRR here reflects how reports are coded.
Not in label — unassessed Not found in the label text, not an artifact pattern. This is a genuine candidate for a formal causality assessment (Bradford Hill / WHO-UMC); it has NOT had one here.

Strongest disproportionality signals

Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only and flags pairs whose reports are unusually skewed by sex or come mostly from consumers rather than clinicians. 3 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.

Show: hide coding/lab/outcome terms hide indication terms unlabeled only hide PRR-only

Reaction	Reports	PRR 95% CI · ROR · χ²/p	EBGM EB05 · IC025	Label screen	Serious-only & strata	Trial cross-check
Product preparation error	24	24.9 16.8–37.0ROR 25.5 · χ² 527 / p 5e-117	24.5 EB05 17.3 · IC025 +3.4 3/3 methods agree	Reporting / coding artifact	–	no trial data cached
Flank pain	7	16.1 7.7–33.7ROR 16.2 · χ² 84 / p 2e-20	13.3 EB05 5.4 · IC025 +1.7 3/3 methods agree	Not in label — unassessed	serious PRR 7.8	no trial data cached
Infusion site pain	8	13.5 6.8–26.9ROR 13.6 · χ² 80 / p 2e-19	10.9 EB05 4.9 · IC025 +1.7 3/3 methods agree	Labeled (related wording) related wording	serious n=3	no trial data cached
Poor quality product administered	5	10.5 4.4–25.2ROR 10.6 · χ² 34 / p 3e-9	6.7 EB05 2.8 · IC025 +0.9 3/3 methods agree	Not in label — unassessed	–	no trial data cached
Anaphylactic reaction (severe allergic reaction)	25	9.8 6.6–14.4ROR 10.0 · χ² 189 / p 3e-43	9.0 EB05 6.2 · IC025 +2.4 3/3 methods agree	Labeled adverse reaction exact term	serious PRR 13.0	no trial data cached
Infusion related reaction (reaction during infusion)	29	9.4 6.6–13.5ROR 9.7 · χ² 211 / p 4e-48	8.7 EB05 6.2 · IC025 +2.4 3/3 methods agree	Labeled adverse reaction exact term	serious PRR 11.7 · 93% clinician	no trial data cached
Injection site extravasation	5	8.6 3.6–20.6ROR 8.6 · χ² 26 / p 1e-7	5.5 EB05 2.4 · IC025 +0.8 3/3 methods agree	Not in label — unassessed	–	no trial data cached
Drug resistance	9	7.5 3.9–14.4ROR 7.6 · χ² 45 / p 1e-11	5.8 EB05 3.2 · IC025 +1.3 3/3 methods agree	Reporting / coding artifact	serious PRR 11.0	no trial data cached
Pruritus generalised	7	6.9 3.3–14.3ROR 6.9 · χ² 29 / p 3e-8	5.0 EB05 2.6 · IC025 +1.0 3/3 methods agree	Not in label — unassessed	serious PRR 13.2	no trial data cached
Product storage error	24	6.0 4.0–8.8ROR 6.1 · χ² 95 / p 1e-22	5.4 EB05 3.8 · IC025 +1.8 3/3 methods agree	Reporting / coding artifact	92% clinician	no trial data cached
Drug reaction with eosinophilia and systemic symptoms	7	5.9 2.8–12.3ROR 5.9 · χ² 24 / p 6e-7	4.4 EB05 2.3 · IC025 +0.8 3/3 methods agree	Labeled (related wording) related wording	serious PRR 7.6	no trial data cached

Trial evidence (ClinicalTrials.gov)

Trial cross-check not yet run for this drug (ClinicalTrials.gov pull covers the 800 most-reported drugs first).

Most frequently reported reactions

By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.

Reaction	Reports	PRR 95% CI · ROR · χ²/p	EBGM EB05 · IC025	Label screen	Serious-only & strata	Trial cross-check
Infusion related reaction (reaction during infusion)	29	9.4 6.6–13.5ROR 9.7 · χ² 211 / p 4e-48	8.7 EB05 6.2 · IC025 +2.4 3/3 methods agree	Labeled adverse reaction exact term	serious PRR 11.7 · 93% clinician	no trial data cached
Anaphylactic reaction (severe allergic reaction)	25	9.8 6.6–14.4ROR 10.0 · χ² 189 / p 3e-43	9.0 EB05 6.2 · IC025 +2.4 3/3 methods agree	Labeled adverse reaction exact term	serious PRR 13.0	no trial data cached
Product storage error	24	6.0 4.0–8.8ROR 6.1 · χ² 95 / p 1e-22	5.4 EB05 3.8 · IC025 +1.8 3/3 methods agree	Reporting / coding artifact	92% clinician	no trial data cached
Product preparation error	24	24.9 16.8–37.0ROR 25.5 · χ² 527 / p 5e-117	24.5 EB05 17.3 · IC025 +3.4 3/3 methods agree	Reporting / coding artifact	–	no trial data cached
Drug resistance	9	7.5 3.9–14.4ROR 7.6 · χ² 45 / p 1e-11	5.8 EB05 3.2 · IC025 +1.3 3/3 methods agree	Reporting / coding artifact	serious PRR 11.0	no trial data cached
Infusion site pain	8	13.5 6.8–26.9ROR 13.6 · χ² 80 / p 2e-19	10.9 EB05 4.9 · IC025 +1.7 3/3 methods agree	Labeled (related wording) related wording	serious n=3	no trial data cached
Drug reaction with eosinophilia and systemic symptoms	7	5.9 2.8–12.3ROR 5.9 · χ² 24 / p 6e-7	4.4 EB05 2.3 · IC025 +0.8 3/3 methods agree	Labeled (related wording) related wording	serious PRR 7.6	no trial data cached
Pruritus generalised	7	6.9 3.3–14.3ROR 6.9 · χ² 29 / p 3e-8	5.0 EB05 2.6 · IC025 +1.0 3/3 methods agree	Not in label — unassessed	serious PRR 13.2	no trial data cached
Flank pain	7	16.1 7.7–33.7ROR 16.2 · χ² 84 / p 2e-20	13.3 EB05 5.4 · IC025 +1.7 3/3 methods agree	Not in label — unassessed	serious PRR 7.8	no trial data cached
Injection site extravasation	5	8.6 3.6–20.6ROR 8.6 · χ² 26 / p 1e-7	5.5 EB05 2.4 · IC025 +0.8 3/3 methods agree	Not in label — unassessed	–	no trial data cached
Poor quality product administered	5	10.5 4.4–25.2ROR 10.6 · χ² 34 / p 3e-9	6.7 EB05 2.8 · IC025 +0.9 3/3 methods agree	Not in label — unassessed	–	no trial data cached
Inappropriate antidiuretic hormone secretion	4	8.4 3.2–22.5ROR 8.5 · χ² 19 / p 5e-6	5.0 EB05 2.0 · IC025 +0.4 3/3 methods agree	Not in label — unassessed	serious PRR 11.1	no trial data cached
Pharyngeal swelling	4	9.0 3.4–23.9ROR 9.0 · χ² 21 / p 2e-6	5.3 EB05 2.1 · IC025 +0.5 3/3 methods agree	Not in label — unassessed	serious n=2	no trial data cached
Haematotoxicity	4	9.3 3.5–24.7ROR 9.3 · χ² 22 / p 1e-6	5.4 EB05 2.2 · IC025 +0.5 3/3 methods agree	Not in label — unassessed	serious PRR 12.4	no trial data cached

Unlabeled candidate signals

Every screened signal with n ≥ 20 was either labeled, an indication term, or an artifact pattern — no unlabeled candidate stood out in the top signals.

Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.

Common questions

What are the most reported side effects of Dalbavancin?

In FDA FAERS, the most frequently co-reported reaction terms for Dalbavancin are infusion related reaction, anaphylactic reaction, infusion site pain, drug reaction with eosinophilia and systemic symptoms, pruritus generalised, flank pain. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.

Does Dalbavancin have an FDA boxed warning?

No. The FDA label retrieved for Dalbavancin has no boxed warning; see the label's Warnings and Precautions for the recognised risks.

Do FAERS signals prove that Dalbavancin causes these side effects?

No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.

Sources & methods

FDA label via openFDA (set ID 966995bb-9d92-434d-b75a-1786072b81c9, effective 20251203; matched on openfda.generic_name.exact:"DALBAVANCIN")
Bayesian shrinkage measures computed offline over all 1,317,300 cached pairs: BCPNN information component (IC, with Norén closed-form IC025) and MGPS empirical-Bayes geometric mean (EBGM, EB05) with a two-component gamma prior fitted by maximum marginal likelihood (α₁=0.57, β₁=0.02, α₂=1.42, β₂=0.70, w=0.17); unstratified
FAERS pair statistics from the OpenPV build of 2026-09-14 (openFDA count= aggregation, field patient.drug.openfda.generic_name.exact, 14 reaction terms, min 3 co-reports); PRR/ROR with 95% CI, chi-square with Yates correction
Serious-only and stratified counts (serious:1, patient.patientsex, primarysource.qualification) from openFDA count queries; serious-only PRR uses the drug serious report total and the term global serious total (N_serious=11,882,979); strata shown only when n ≥ 20
Seriousness and sex counts from openFDA count=serious, patient.patientsex, seriousnessdeath

Page generated 2026-10-08. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.